Perrigo Starts Supply Chain Overhaul After Filing OTC Birth Control NDA, Launching Nasonex Switch
Along with Q2 results including reported net sales up 14.3% to $1.12bn, Perrigo announces overhaul of its supply chain expected to generate $100m to $300m in net cost savings and creation of women's health, skin care business units.
You may also be interested in...
Perrigo Adds Good Start Brand In $230M Statement On Boosting Infant Formula Production Capacity
Good Start formula line marketed in US and in Canada will move to Perrigo from Nestle along with a formula plant in Wisconsin, where Perrigo will expand current 29mil pound annual production capacity to 36m within 18 months. Good Start available in US as part of iconic Gerber brand and under Nestle brand in Canada.
US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?
Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.
FDA Moves On NDA For First US OTC Birth Control, Scheduling Joint Ad Comm Meeting
The US FDA has scheduled a joint advisory committee meeting for November to review Perrigo subsidiary HRA Pharma’s new drug application for Rx-to-OTC switch of Opill (0.075-mg norgestrel), which would represent the first birth control pill available in the US without a prescription.